US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.69

-0.1040-1.80%

Volume:55.60K

Turnover:312.37K

Market Cap:123.37M

PE:-1.77

High:5.78

Open:5.70

Low:5.31

Close:5.79

52wk High:17.94

52wk Low:3.35

Shares:21.70M

Float Shares:11.17M

Volume Ratio:1.19

T/O Rate:0.50%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2080

EPS(LYR):-0.7400

ROE:-66.02%

ROA:-40.38%

PB:1.65

PE(LYR):-7.68

Loading ...

Overview Company News Filings

Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Major AARD Stock Drops

Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops

Aardvark Therapeutics Shareholders Approve Governance and Incentives

Aardvark Therapeutics Held Annual Shareholder Meeting

Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)

PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall

Grace Therapeutics Q1 Net Loss Widens on Impairment Charges

Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

Indaptus Q2 Net Loss Narrows as Costs Fall

AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges

Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition

Aardvark Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains

Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Douglas AG (OtherDOUDF) and Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction

Aardvark Therapeutics Inc Q2 Net Income USD -14.387 Million VS. Ibes Estimate USD -20.6 Million

THOMSON REUTERS

Aardvark Therapeutics Q2 EPS $-0.66

THOMSON REUTERS

Aardvark Therapeutics Inc Q2 Operating Expenses USD 15.084 Million

THOMSON REUTERS

Aardvark Therapeutics Inc Q2 Income from Operations USD -15.084 Million

THOMSON REUTERS

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/AARD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.686,"timestamp":1788192730991,"preClose":5.79,"halted":0,"volume":55597,"delay":0,"changeRate":-0.01796200345423145,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"Trading","change":-0.104,"latestTime":"08-31 12:12:17 EDT","open":5.7,"high":5.78,"low":5.31,"amount":312367.963904,"amplitude":0.081174,"askPrice":5.76,"askSize":10,"bidPrice":5.68,"bidSize":51,"shortable":0,"etf":0,"ttmEps":-3.207951,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.79,"preHourTrading":{"tag":"盘前","latestPrice":6,"preClose":5.79,"latestTime":"08:48 EDT","volume":323,"amount":1941.279742,"timestamp":1788180491861,"change":0.21,"changeRate":0.036269,"amplitude":0.170984},"postHourTrading":{"tag":"盘后","latestPrice":6.4,"preClose":5.79,"latestTime":"19:50 EDT","volume":680,"amount":4177.5036,"timestamp":1787961050763,"change":0.61,"changeRate":0.105354,"amplitude":0.105354},"volumeRatio":1.192384,"impliedVol":2.4167,"impliedVolPercentile":0.8693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":11168300,"roa":"-40.38%","roe":"-66.02%","lyrEps":-0.74,"volumeRatio":1.192384,"shares":21696893,"dividePrice":0,"high":5.78,"amplitude":0.081174,"preClose":5.79,"low":5.31,"week52Low":3.35,"pbRate":"1.65","week52High":17.94,"institutionHeld":0,"latestPrice":5.686,"committee":0.672131,"eps":-3.207951,"divideRate":0,"volume":55597,"delay":0,"ttmEps":-3.207951,"open":5.7,"prevYearClose":13.125,"prevWeekClose":5.79,"prevMonthClose":6.6,"prevQuarterClose":5.76,"fiveDayClose":6.88,"twentyDayClose":7.08,"sixtyDayClose":3.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"AARD","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-05-07","symbol":"AARD","fiscalQuarterEnding":"2026/03","expectedEps":-0.81,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.99},{"market":"US","date":"2026-03-23","symbol":"AARD","fiscalQuarterEnding":"2025/12","expectedEps":-0.81,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-08-28","current":-1.784628,"percent":0.772846,"low":-51.17654,"twenty":-9.421915,"median":-6.102695,"eighty":-2.029869,"high":-1.08662,"avg":-7.764443,"sd":8.347013,"marketCap":144877680},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410},{"date":"2026-03-20","current":-2.187506,"twenty":-10.558368,"median":-7.450451,"eighty":-5.647336,"marketCap":106689032},{"date":"2026-03-27","current":-1.329623,"twenty":-10.505146,"median":-7.272172,"eighty":-5.612515,"marketCap":76574303},{"date":"2026-04-02","current":-1.549332,"twenty":-10.461316,"median":-7.114571,"eighty":-5.565193,"marketCap":89227607},{"date":"2026-04-10","current":-1.477359,"twenty":-10.383939,"median":-7.072594,"eighty":-5.510729,"marketCap":85082559},{"date":"2026-04-17","current":-1.890261,"twenty":-10.268548,"median":-6.92859,"eighty":-5.336927,"marketCap":108862044},{"date":"2026-04-24","current":-2.034209,"twenty":-10.187377,"median":-6.86609,"eighty":-5.089336,"marketCap":117152140},{"date":"2026-05-01","current":-2.056938,"twenty":-10.153251,"median":-6.792493,"eighty":-4.960237,"marketCap":118461102},{"date":"2026-05-08","current":-1.748556,"twenty":-10.125375,"median":-6.716536,"eighty":-4.705593,"marketCap":122169829},{"date":"2026-05-15","current":-2.101422,"twenty":-10.043581,"median":-6.685898,"eighty":-4.518505,"marketCap":146824271},{"date":"2026-05-22","current":-1.408234,"twenty":-9.951007,"median":-6.641483,"eighty":-4.307154,"marketCap":98391896},{"date":"2026-05-29","current":-1.311437,"twenty":-9.918135,"median":-6.60716,"eighty":-4.188404,"marketCap":91628817},{"date":"2026-06-05","current":-1.230253,"twenty":-9.857086,"median":-6.549693,"eighty":-2.633043,"marketCap":85956556},{"date":"2026-06-12","current":-1.136579,"twenty":-9.835549,"median":-6.495974,"eighty":-2.45715,"marketCap":79411641},{"date":"2026-06-18","current":-1.192783,"twenty":-9.824539,"median":-6.468768,"eighty":-2.34822,"marketCap":83338590},{"date":"2026-06-26","current":-1.57997,"twenty":-9.822648,"median":-6.449019,"eighty":-2.187506,"marketCap":110390908},{"date":"2026-07-02","current":-1.754828,"twenty":-9.791341,"median":-6.425331,"eighty":-2.13573,"marketCap":122608083},{"date":"2026-07-10","current":-1.561235,"twenty":-9.726041,"median":-6.368321,"eighty":-2.087243,"marketCap":109081925},{"date":"2026-07-17","current":-1.976523,"twenty":-9.645626,"median":-6.354268,"eighty":-2.066183,"marketCap":138097717},{"date":"2026-07-24","current":-1.995258,"twenty":-9.546006,"median":-6.285834,"eighty":-2.034209,"marketCap":139406700},{"date":"2026-07-31","current":-1.998381,"twenty":-9.523603,"median":-6.216183,"eighty":-2.015866,"marketCap":139624864},{"date":"2026-08-07","current":-2.279403,"twenty":-9.505361,"median":-6.182531,"eighty":-2.029869,"marketCap":159259610},{"date":"2026-08-14","current":-2.007209,"twenty":-9.48453,"median":-6.16129,"eighty":-2.029869,"marketCap":140281862},{"date":"2026-08-21","current":-1.844378,"twenty":-9.46418,"median":-6.116088,"eighty":-2.0169,"marketCap":128901742},{"date":"2026-08-28","current":-2.072968,"twenty":-9.421915,"median":-6.102695,"eighty":-2.029869,"marketCap":144877680}],"updateTime":1788192737230},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662082041","title":"Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Major AARD Stock Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2662082041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662082041?lang=en_us&edition=fundamental","pubTime":"2026-08-28 01:47","pubTimestamp":1787852846,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing a federal securities lawsuit alleging that investors were misled about the safety, tolerabilit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aardvark-therapeutics-lawsuit-alleges-investors-were-misled-before-major-aard-stock-drops?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aardvark-therapeutics-lawsuit-alleges-investors-were-misled-before-major-aard-stock-drops?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ","JEPQ","TQQY","QQQE","QDTE","QQQY","QQQA","NDX","NQmain","SQQQ","ISBC","GPIQ","NVIW.SI","AARD","TECS","PSQ","MNQmain","BK4211","IYW","QQQM",".IXIC","QID","QYLG","QQQ","QLD","BK4007","TQQQ","FTEC","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661329772","title":"Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2661329772","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661329772?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:18","pubTimestamp":1787257097,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing a federal securities lawsuit alleging that investors were misled about the safety profile, reg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aardvark-therapeutics-lawsuit-alleges-investors-were-misled-before-sharp-aard-stock-drops?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aardvark-therapeutics-lawsuit-alleges-investors-were-misled-before-sharp-aard-stock-drops?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QDTE","IYW","QYLG","BK4007","TQQQ","NVIW.SI","TQQY","ISBC","FTEC","JEPQ",".IXIC","QLD","TECS","QQQM","BK4211","NQmain","ONEQ","QQQA","SQQQ","QQQY","QQQ","GPIQ","NDX","QID","MNQmain","QQQJ","AARD","QQQE","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660087432","title":"Aardvark Therapeutics Shareholders Approve Governance and Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2660087432","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660087432?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:56","pubTimestamp":1787000185,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Aardvark Therapeutics, Inc. ( ($AARD) ). At its August 14, 2026 annual meeting, Aardvark Therapeutics, Inc. rec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-shareholders-approve-governance-and-incentives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-shareholders-approve-governance-and-incentives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660434014","title":"Aardvark Therapeutics Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2660434014","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660434014?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:11","pubTimestamp":1786997466,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics held annual shareholder meetingAardvark Therapeutics held its 2026 annual shareholder meeting on Aug. 14, 2026.Shareholders ratified BDO USA as independent auditor for the year e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLPz3gH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659123665","title":"Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659123665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659123665?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:40","pubTimestamp":1786725608,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-nakamoto-inc-naka-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-nakamoto-inc-naka-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NA","BK4141","BK4007","BK4196","NAKA","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659508152","title":"PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659508152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659508152?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:39","pubTimestamp":1786624789,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Q2 net loss widens slightly as operating costs fallOverviewUS cancer immunotherapy developer's Q2 net loss widened slightly yr/yrOperating expenses fell due to lower clinical trial a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PDSB","CRDF","IMNM","BK4139","BK4563","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154351","title":"Grace Therapeutics Q1 Net Loss Widens on Impairment Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154351","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154351?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:08","pubTimestamp":1786622937,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Q1 net loss widens on impairment chargesOverviewUS biopharma firm's Q1 net loss widened on impairment charges tied to deprioritized programsResearch and admin expenses fell as GTx-1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","AARD","ELOX","GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151345","title":"Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151345","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151345?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:35","pubTimestamp":1786620948,"startTime":"0","endTime":"0","summary":"In a report released today, James Condulis from Stifel Nicolaus reiterated a Hold rating on Aardvark Therapeutics, Inc., with a price target of $6....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659567411","title":"Indaptus Q2 Net Loss Narrows as Costs Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659567411","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659567411?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:16","pubTimestamp":1786619798,"startTime":"0","endTime":"0","summary":"Indaptus Q2 net loss narrows as costs fallOverviewU.S. immunotherapy biotech's Q2 net loss narrowed, driven by lower clinical and payroll costsCompany discontinued Decoy20 clinical study and has no ac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","AARD","TXMD","BK4139","BK4007","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135164","title":"AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135164","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135164?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:00","pubTimestamp":1786600830,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has disclosed a new risk, in the Technology category. Aardvark Therapeutics, Inc. faces material risk from its p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ai-risk-and-regulation-how-aardvark-therapeutics-use-of-artificial-intelligence-could-expose-it-to-compliance-cybersecurity-and-competitiveness-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ai-risk-and-regulation-how-aardvark-therapeutics-use-of-artificial-intelligence-could-expose-it-to-compliance-cybersecurity-and-competitiveness-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTY","AARD","TEKX","BK4585","QTOC","VTHR","AIPO","NTSK","IHAK","BK4007","AGIX","BK4097","CIBR","HACK","BK4588","CHAT","BUG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900653","title":"Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900653","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900653?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565663,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Q2 revenue falls on deferred revenue recognitionOverviewUS T-cell immunotherapy developer's Q2 revenue beat analyst expectations, but fell sharply yr/yrCompany reported Q2 net lo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N449110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4139","BK4007","ATRA","PLRX","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658905961","title":"Aardvark Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658905961","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658905961?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:41","pubTimestamp":1786545706,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryAardvark Therapeutics, Inc.AARD.OQreported a quarterly adjusted loss of 66 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971236","title":"Cypherpunk Technologies Swings to Q2 Profit on Zcash Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971236","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971236?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:14","pubTimestamp":1786533258,"startTime":"0","endTime":"0","summary":"Cypherpunk Technologies swings to Q2 profit on Zcash gainsOverviewUS privacy tech firm's Q2 net income turned positive, driven by unrealized gains on Zcash holdingsQ2 diluted EPS was $0.18, reversing ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYPH","AARD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658758689","title":"Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Douglas AG (OtherDOUDF) and Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658758689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658758689?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:20","pubTimestamp":1786526421,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Smithfield Foods (SFD), Douglas AG (DOUDF) and Aardvark Therapeutics, Inc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-smithfield-foods-sfd-douglas-ag-otherdoudf-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-smithfield-foods-sfd-douglas-ag-otherdoudf-and-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SILJ","BK4210","SFD","BK4212","DOUDF","SLJY","SLVX","NA","BK4007","SLVR","FXG","BK4200","AARD","AG","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945726","title":"Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945726","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945726?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:04","pubTimestamp":1786482254,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reductionOverviewUS biopharma firm's Q2 net loss narrowed and beat analyst expectationsOperating expens","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N44812F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4139","AARD","BOLT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945165","title":"Aardvark Therapeutics Inc Q2 Net Income USD -14.387 Million VS. Ibes Estimate USD -20.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945143","title":"Aardvark Therapeutics Q2 EPS $-0.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945143?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658894516","title":"Aardvark Therapeutics Inc Q2 Operating Expenses USD 15.084 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658894516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658894516?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451669","title":"Aardvark Therapeutics Inc Q2 Income from Operations USD -15.084 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451669?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXG3XWTT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BMED","HYLG","BK4007","NVIB","PWS","MEDX","IDNA","IND","GDOC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":95,"code":"91000000","status":"200"}]}}